Palisade Bio Inc. (PALI): Price and Financial Metrics

Palisade Bio Inc. (PALI): $0.44

0.01 (+2.28%)

POWR Rating

Component Grades

Momentum

D

Stability

F

Sentiment

Quality

D

Add PALI to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#312 of 347

in industry

PALI Price/Volume Stats

Current price $0.44 52-week high $3.65
Prev. close $0.43 52-week low $0.41
Day low $0.43 Volume 137,900
Day high $0.45 Avg. volume 4,678,841
50-day MA $0.55 Dividend yield N/A
200-day MA $0.97 Market Cap 4.08M

PALI Stock Price Chart Interactive Chart >

PALI POWR Grades

  • Growth is the dimension where PALI ranks best; there it ranks ahead of 75.17% of US stocks.
  • The strongest trend for PALI is in Growth, which has been heading down over the past 152 days.
  • PALI's current lowest rank is in the Stability metric (where it is better than 1.46% of US stocks).

PALI Stock Summary

  • PALI has a higher market value than just 2.61% of US stocks; more precisely, its current market capitalization is $5,124,724.
  • PALI's price/sales ratio is 20.5; that's higher than the P/S ratio of 94.37% of US stocks.
  • PALISADE BIO INC's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -209.96%, greater than the shareholder yield of just 2.14% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to PALISADE BIO INC are LUMO, OGEN, MEIP, XBIO, and NVEC.
  • PALI's SEC filings can be seen here. And to visit PALISADE BIO INC's official web site, go to www.senecabio.com.

PALI Valuation Summary

  • In comparison to the median Healthcare stock, PALI's price/sales ratio is 414.29% higher, now standing at 21.6.
  • PALI's EV/EBIT ratio has moved up 30.7 over the prior 204 months.

Below are key valuation metrics over time for PALI.

Stock Date P/S P/B P/E EV/EBIT
PALI 2023-12-29 21.6 0.4 -0.4 0.7
PALI 2023-12-28 24.0 0.4 -0.5 0.7
PALI 2023-12-27 22.0 0.4 -0.4 0.7
PALI 2023-12-26 22.0 0.4 -0.4 0.7
PALI 2023-12-22 22.0 0.4 -0.4 0.7
PALI 2023-12-21 22.0 0.4 -0.4 0.7

Palisade Bio Inc. (PALI) Company Bio


Palisade Bio is a biopharmaceutical company focused on developing therapeutics that protect the integrity of the intestinal barrier. The Company utilizes over three decades of research and established science that links the role of intestinal barrier biology and human disease to develop novel therapeutics that target and improve the integrity of the intestinal barrier. The Company’s lead program, LB1148, is a broad-spectrum serine protease inhibitor which acts to neutralize digestive enzymes, potentially reducing intestinal damage. In clinical studies, LB1148 has demonstrated positive results in reducing the incidence and severity of post-surgical abdominal adhesions and accelerating the time to return of postoperative bowel function. LB1148 is being investigated in a Phase 2 study to evaluate return of gastrointestinal function, post-operative ileus and intra-abdominal adhesions in subjects undergoing elective bowel resection. (copied from company website @ https://www.palisadebio.com/about-us/)


PALI Latest News Stream


Event/Time News Detail
Loading, please wait...

PALI Latest Social Stream


Loading social stream, please wait...

View Full PALI Social Stream

Latest PALI News From Around the Web

Below are the latest news stories about PALISADE BIO INC that investors may wish to consider to help them evaluate PALI as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

It's time to start the day with a breakdown of the biggest pre-market stock movers worth keeping an eye on for Thursday!

William White on InvestorPlace | November 16, 2023

Palisade Bio Reports Third Quarter 2023 Financial Results and Provides Business Outlook

– Transformational transaction jumpstarts development pipeline into high-value inflammatory bowel disease (IBD) market – Lead program, PALI-2108, oral prodrug therapy for the treatment of moderate-to-severe ulcerative colitis (UC) is anticipated to commence Phase 1 clinical study in 2024 – Strong financial position with cash to execute on strategy and achieve significant milestones into 2025 Carlsbad, CA, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade

Yahoo | November 10, 2023

Palisade Bio to Participate at the Virtual Investor Ask the CEO Conference

Live moderated webcast with J.D. Finley, Chief Executive Officer of Palisade Bio on Wednesday, October 25th at 2:00 PM ET Carlsbad, CA, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Palisade Bio (Nasdaq: PALI), a biopharmaceutical company focused on developing novel therapeutics for serious chronic gastrointestinal (GI) diseases, today announced that J.D. Finley, Chief Executive Officer of Palisade Bio will participate at the Virtual Investor Ask the CEO Conference on Wednesday, October 25, 2023 at 2:00 PM

Yahoo | October 11, 2023

Insider Buying: John Finley Acquires 15,000 Shares of Palisade Bio Inc

On September 13, 2023, John Finley, CEO, CFO, and Director of Palisade Bio Inc (NASDAQ:PALI), made a significant insider purchase of 15,000 shares of the company's stock.

Yahoo | September 14, 2023

Palisade Bio Announces Closing of $2 Million Registered Direct Offering Priced At Market Under Nasdaq Rules

Carlsbad, CA, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, is announcing today that it has closed its previously announced registered direct offering with institutional investors for the purchase of 2,339,398 shares of common stock for gross proceeds of $1,965,094.32. Ladenburg Thalmann & Co. Inc. acted as the exclusive placement agent for the registered direct offe

Yahoo | September 11, 2023

Read More 'PALI' Stories Here

PALI Price Returns

1-mo -16.98%
3-mo N/A
6-mo -30.38%
1-year -79.53%
3-year -99.92%
5-year -100.00%
YTD -25.42%
2023 -88.65%
2022 -92.00%
2021 -75.38%
2020 -99.70%
2019 -99.20%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!